McFarlane Neil F. 4

What Happened

• Neil F. McFarlane, President, CEO and Director of Zevra Therapeutics, had one-third of a restricted stock unit (RSU) award vest and settle on Feb 7, 2026. The filing reports 37,500 shares acquired and 37,500 shares disposed at $0 (reflecting withholding/surrender to satisfy tax obligations), for a total of 75,000 shares involved in the vesting/settlement.
• On Feb 9, 2026, McFarlane sold 14,625 shares in the open market under a pre-existing 10b5-1 trading plan, at a weighted average price of $8.56 per share, generating proceeds of $125,186.

Key Details

• Transaction dates: Feb 7, 2026 (RSU vesting/conversion); Feb 9, 2026 (open-market sale).
• Sale price/details: 14,625 shares sold at a weighted average of $8.56; trades ranged $8.39–$8.67 (per filing footnote).
• Proceeds: $125,186 from the open-market sale.
• Vesting schedule: Footnote states one-third vested/settled on Feb 7, 2026; the remaining two-thirds vest and settle in two equal annual installments thereafter, subject to continued service.
• 10b5-1 plan: Sale executed under a 10b5-1 plan adopted 3/21/2025 (per footnote).
• Shares owned after transaction: Not specified in the excerpt provided.
• Filing: Report filed Feb 10, 2026, covering the Feb 7 and Feb 9 transactions (no late-filing indicator shown in the provided excerpt).

Context

• The Feb 7 entries reflect conversion/settlement of RSUs (derivative code M) with a portion of shares withheld or surrendered to cover taxes (reported as a $0 disposition).
• The Feb 9 sale was executed under a pre-established trading plan (10b5-1); such plans regularly govern timing and execution of insider sales and are disclosed in the filing.
• The filing is factual about the transactions; it does not state the insider’s motivations.